Ignite Creation Date:
2025-12-25 @ 12:04 AM
Ignite Modification Date:
2026-02-24 @ 3:52 AM
Study NCT ID:
NCT07084558
Status:
RECRUITING
Last Update Posted:
2025-10-28
First Post:
2025-07-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness
Sponsor:
Austrian Breast & Colorectal Cancer Study Group
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Early and Locally Advanced Breast Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | early breast cancer | View |
| None | locally advanced breast cancer | View |
| None | neoadjuvant endocrine therapy | View |
| None | chemotherapy | View |
| None | HR-positive | View |
| None | HER2-negative | View |
| None | ABCSG 61 | View |
| None | TEODOR | View |
| None | endocrine responsive | View |
| None | Natera | View |
| None | in-vitro diagnostic | View |
| None | Signatera Test | View |
| None | Signatera | View |
| None | ctDNA | View |